The potential of nasal application for delivery to the central brain - A microdialysis study of fluorescein in rats

European Journal of Pharmaceutical Sciences

Volumn 21, Issue 2-3, 2004, Pages 235-242

  Bagger, Morten Aavad ^a   Bechgaard, Erik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Microdialysis; Nasal drug delivery; Olfactory pathway; Pharmacokinetics; Rats; Sodium fluorescein

Indexed keywords

FLUORESCEIN SODIUM;

ABSORPTION; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ESOPHAGUS OBSTRUCTION; HYDROPHILICITY; IMPLANTATION; MALE; MICRODIALYSIS; MOLECULAR PROBE; NONHUMAN; OLFACTORY SYSTEM; PERMEABILITY; PRIORITY JOURNAL; RAT;

EID: 0742304311     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.10.012     Document Type: Article

References (24)

1. Bickel U., Schumacher O.P., Kang Y.S., Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278:1996;107-113.
2. Bouw M.R., Xie R., Tunblad K., Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats - pharmacokinetic/pharmacodynamic modelling. Br. J. Pharmacol. 134:2001;1796-1804.
3. Chou K.J., Donovan M.D. Lidocaine distribution into the CNS following nasal and arterial delivery: a comparison of local sampling and microdialysis techniques. Int. J. Pharm. 171:1998;53-61.
4. Chow H.H., Anavy N., Villalobos A. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J. Pharm. Sci. 90:2001;1729-1735.
5. Chow H.H., Chen Z., Matsuura G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci. 88:1999;754-758.
6. Dahlin M., Bergman U., Jansson B., Bjork E., Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res. 17:2000;737-742.
7. Derad I., Willeke K., Pietrowsky R., Born J., Fehm H.L. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am. J. Hypertens. 11:1998;971-977.
8. Eriksson C., Bergman U., Franzen A., Sjoblom M., Brittebo E.B. Transfer of some carboxylic acids in the olfactory system following intranasal administration. J. Drug Target. 7:1999;131-142.
9. Huai-Yun H., Secrest D.T., Mark K.S., Carney D., Brandquist C., Elmquist W.F., Miller D.W. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem. Biophys. Res. Commun. 243:1998;816-820.
10. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11:2000;1-18.
11. Kristensson K., Olsson Y. Uptake of exogenous protein in mouse olfactory cells. Acta Neuropathol. 19:1971;145-154.
12. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discovery Today. 6:2001;206-212.
13. Mathison S., Nagilla R., Kompella U.B. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J. Drug Target. 5:1998;415-441.
14. Pardridge, W.M., 2001. Brain Drug Tageting. The Future of Brain Drug Development. Cambridge University Press, pp. 13-35.
15. Pietrowsky R., Claassen L., Frercks H., Fehm H.L., Born J. Time course of intranasally administered cholecystokinin-8 on central nervous effects. Neuropsychobiology. 43:2001;254-259.
16. Pietrowsky R., Struben C., Molle M., Fehm H.L., Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol. Psychiat. 39:1996a;332-340.
17. Pietrowsky R., Thiemann A., Kern W., Fehm H.L., Born J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology. 21:1996b;559-572.
18. Silva M.A., Mattern C., Hacker R., Tomaz C., Huston J.P., Schwarting R.K. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse. 27:1997;294-302.
19. Souza-Silva M.A., Mattern C., Hacker R., Nogueira P.J., Huston J.P., Schwarting R.K. Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat. J. Neurochem. 68:1997;233-239.
20. Stain-Texier F., Boschi G., Sandouk P., Scherrmann J.M. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br. J. Pharmacol. 128:1999;917-924.
21. Sun H., Bungay P.M., Elmquist W.F. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. J. Pharmacol. Exp. Ther. 297:2001a;991-1000.
22. Sun H., Johnson D.R., Finch R.A., Sartorelli A.C., Miller D.W., Elmquist W.F. Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem. Biophys. Res. Commun. 284:2001b;863-869.
23. Wang Y., Aun R., Tse F.L. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm. Drug Dispos. 19:1998;571-575.
24. Wu D., Kang Y.S., Bickel U., Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos. 25:1997;768-771.